Pharmacokinetics and Pharmacodynamics of Antifungals in Children: Clinical Implications

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Drugs

• Publication date

  2014-05-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40265-014-0227-3PMID 24872147PMCID PMC4073603
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synthesis and Antifungal Activity of ASP9726, a Novel Echinocandin with Potent Aspergillus hyphal Growth Inhibition.

  2014cited by this paper
• Synthesis and antifungal activity of ASP9726, a novel echinocandin with potent Aspergillus hyphal growth inhibition.

  2014cited by this paper
• Safety and Pharmacokinetic Profiles of Repeated-dose Micafungin in Children and Adolescents Treated for Invasive Candidiasis

  2013cited by this paper
• Isavuconazole Pharmacodynamic Target Determination for Candida Species in an In Vivo Murine Disseminated Candidiasis Model

  2013cited by this paper
• Correlation of CYP2C19 Phenotype With Voriconazole Plasma Concentration in Children

  2013cited by this paper
• Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity.

  2013cited by this paper
• A Phase 1, randomized, open-label crossover study to evaluate the safety and pharmacokinetics of 400 mg albaconazole administered to healthy participants as a tablet formulation versus a capsule formulation

  2013cited by this paper
• Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients.

  2012cited by this paper
• The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial.

  2012cited by this paper
• Antifungal Therapy and Outcomes in Infants With Invasive Candida Infections

  2012cited by this paper
• Integrated Population Pharmacokinetic Analysis of Voriconazole in Children, Adolescents, and Adults

  2012cited by this paper
• Voriconazole-induced Phototoxicity in Children

  2012cited by this paper
• Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation

  2012cited by this paper
• Safety and Pharmacokinetics of Multiple‐Dose Anidulafungin in Infants and Neonates

  2011cited by this paper
• Population Pharmacokinetics and Pharmacodynamics of Caspofungin in Pediatric Patients

  2011cited by this paper
• Fluconazole Loading Dose Pharmacokinetics and Safety in Infants

  2011cited by this paper
• Comparison of Pharmacokinetics and Safety of Voriconazole Intravenous-to-Oral Switch in Immunocompromised Children and Healthy Adults

  2011cited by this paper
• Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients

  2011cited by this paper
• Comparison of Pharmacokinetics and Safety of Voriconazole Intravenous-to-Oral Switch in Immunocompromised Adolescents and Healthy Adults

  2011cited by this paper
• Safety of Micafungin in Pediatric Clinical Trials

  2011cited by this paper
• Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia.

  2011cited by this paper
• Use of Pharmacokinetic-Pharmacodynamic Analyses To Optimize Therapy with the Systemic Antifungal Micafungin for Invasive Candidiasis or Candidemia

  2011cited by this paper
• The Burden of Infections by Parainfluenza Virus in Hospitalized Children in Spain

  2011cited by this paper
• Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients

  2011cited by this paper
• Phase II Dose Escalation Study of Caspofungin for Invasive Aspergillosis

  2011cited by this paper
• Neonatal Candidiasis: Epidemiology, Risk Factors, and Clinical Judgment

  2010cited by this paper
• Exposure–Response of Posaconazole Used for Prophylaxis Against Invasive Fungal Infections: Evaluating the Need to Adjust Doses Based on Drug Concentrations in Plasma

  2010cited by this paper
• Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus.

  2010cited by this paper
• Voriconazole Pharmacokinetics and Safety in Immunocompromised Children Compared to Adult Patients

  2010cited by this paper
• Voriconazole pharmacokinetics and pharmacodynamics in children.

  2010cited by this paper
• Human Tissue Distribution of Voriconazole

  2010influential reference
• Pharmacokinetics, Safety, and Tolerability of Voriconazole in Immunocompromised Children

  2010cited by this paper
• Population Pharmacokinetics of Micafungin in Neonates and Young Infants

  2010cited by this paper
• Safety and Pharmacokinetics of Repeat‐Dose Micafungin in Young Infants

  2010cited by this paper
• Toxicodynamics of itraconazole: implications for therapeutic drug monitoring.

  2009cited by this paper
• Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

  2009cited by this paper
• Nephrotoxicity Associated With Amphotericin B Deoxycholate in Neonates

  2009cited by this paper
• Association of Fluconazole Pharmacodynamics with Mortality in Patients with Candidemia

  2009cited by this paper
• A Prospective, Multicenter Study of Caspofungin for the Treatment of Documented Candida or Aspergillus Infections in Pediatric Patients

  2009cited by this paper
• Pharmacokinetics of an Elevated Dosage of Micafungin in Premature Neonates

  2009cited by this paper
• Association of Fluconazole Pharmacodynamics with Mortality in Patients with Candidemia

  2008cited by this paper
• Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.

  2008cited by this paper
• In Vitro and In Vivo Antifungal Activities of T-2307, a Novel Arylamidine

  2008cited by this paper
• Population Pharmacokinetics of Fluconazole in Young Infants

  2008cited by this paper
• Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.

  2008cited by this paper
• Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications

  2008cited by this paper
• Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies.

  2008cited by this paper
• Pediatric Invasive Aspergillosis: A Multicenter Retrospective Analysis of 139 Contemporary Cases

  2008cited by this paper
• The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates.

  2008cited by this paper
• Pharmacokinetics and Safety of Caspofungin in Neonates and Infants Less than 3 Months of Age

  2008cited by this paper
• Pharmacokinetics and Tissue Distribution of Anidulafungin in Rats

  2008cited by this paper
• Pharmacokinetics and Safety of Caspofungin in Older Infants and Toddlers

  2008cited by this paper
• Population Pharmacokinetic Analysis of Voriconazole Plasma Concentration Data from Pediatric Studies

  2008cited by this paper
• Micafungin Versus Liposomal Amphotericin B for Pediatric Patients With Invasive Candidiasis: Substudy of a Randomized Double-Blind Trial

  2008cited by this paper
• Therapeutic and prophylactic efficacy of aminocandin (IP960) against disseminated candidiasis in mice.

  2008cited by this paper
• A case of invasive central nervous system aspergillosis treated with micafungin with monitoring of micafungin concentrations in the cerebrospinal fluid

  2007cited by this paper
• A multicenter, randomized trial of prophylactic fluconazole in preterm neonates.

  2007cited by this paper
• Population Pharmacokinetics of Micafungin in Pediatric Patients and Implications for Antifungal Dosing

  2007cited by this paper
• Candida infection in very low birth-weight infants: outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome®)

  2007cited by this paper
• Posaconazole Plasma Concentrations in Juvenile Patients with Invasive Fungal Infection

  2007cited by this paper
• Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.

  2007cited by this paper
• Caspofungin in the treatment of symptomatic candiduria.

  2007cited by this paper
• Correlation of posaconazole minimum fungicidal concentration and time kill test against nine Candida species.

  2007cited by this paper
• In Vivo Pharmacodynamic Characterization of Anidulafungin in a Neutropenic Murine Candidiasis Model

  2007cited by this paper
• Single-Dose Pharmacokinetics of Intravenous Itraconazole and Hydroxypropyl-β-Cyclodextrin in Infants, Children, and Adolescents

  2007cited by this paper
• Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.

  2007cited by this paper
• Evaluation of Amphotericin B Interpretive Breakpoints for Candida Bloodstream Isolates by Correlation with Therapeutic Outcome

  2006cited by this paper
• The Pharmacokinetics and Safety of Micafungin, a Novel Echinocandin, in Premature Infants

  2006cited by this paper
• Safety and Pharmacokinetics of Intravenous Anidulafungin in Children with Neutropenia at High Risk for Invasive Fungal Infections

  2006cited by this paper
• Oral versus Intravenous Flucytosine in Patients with Human Immunodeficiency Virus-Associated Cryptococcal Meningitis

  2006cited by this paper
• High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.

  2006cited by this paper
• Evidence of excessive concentrations of 5-flucytosine in children aged below 12 years: a 12-year review of serum concentrations from a UK clinical assay reference laboratory.

  2006cited by this paper
• Pharmacokinetic-Pharmacodynamic Comparison of Amphotericin B (AMB) and Two Lipid-Associated AMB Preparations, Liposomal AMB and AMB Lipid Complex, in Murine Candidiasis Models

  2006cited by this paper
• In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and Yeasts

  2006cited by this paper
• Single-Ascending-Dose Pharmacokinetics and Safety of the Novel Broad-Spectrum Antifungal Triazole BAL4815 after Intravenous Infusions (50, 100, and 200 Milligrams) and Oral Administrations (100, 200, and 400 Milligrams) of Its Prodrug, BAL8557, in Healthy Volunteers

  2006cited by this paper
• Neonatal Candidiasis Among Extremely Low Birth Weight Infants: Risk Factors, Mortality Rates, and Neurodevelopmental Outcomes at 18 to 22 Months

  2006cited by this paper
• Population Pharmacokinetics of Liposomal Amphotericin B in Pediatric Patients with Malignant Diseases

  2006cited by this paper
• Linear pharmacokinetics of micafungin and its active metabolites in Japanese pediatric patients with fungal infections.

  2006cited by this paper
• Pharmacodynamic Activity of Amphotericin B Deoxycholate Is Associated with Peak Plasma Concentrations in a Neutropenic Murine Model of Invasive Pulmonary Aspergillosis

  2006cited by this paper
• Efficacy and Safety of Amphotericin B Lipid Complex in 548 Children and Adolescents With Invasive Fungal Infections

  2005cited by this paper
• Safety, Tolerability, and Pharmacokinetics of Micafungin (FK463) in Febrile Neutropenic Pediatric Patients

  2005cited by this paper
• In Vitro Activities of Anidulafungin against More than 2,500 Clinical Isolates of Candida spp., Including 315 Isolates Resistant to Fluconazole

  2005cited by this paper
• Itraconazole-related increased vincristine neurotoxicity: case report and review of literature.

  2005cited by this paper
• Population Pharmacokinetics of Amphotericin B Lipid Complex in Neonates

  2005influential reference
• A phase I/II randomized, double‐blind, placebo‐controlled, dose‐ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis

  2005cited by this paper
• In Vitro Activity of Ravuconazole against 923 Clinical Isolates of Nondermatophyte Filamentous Fungi

  2005cited by this paper
• Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection.

  2005cited by this paper
• Pharmacokinetics, Safety, and Tolerability of Caspofungin in Children and Adolescents

  2005influential reference
• Experience with Caspofungin in the Treatment of Persistent Fungemia in Neonates

  2005cited by this paper
• Posaconazole Pharmacokinetics, Safety, and Tolerability in Subjects With Varying Degrees of Chronic Renal Disease

  2005cited by this paper
• The efficacy of two different lipid‐based amphotericin B in neonatal Candida septicemia

  2005cited by this paper
• In Vitro and In Vivo Efficacies of the New Triazole Albaconazole against Cryptococcus neoformans

  2004cited by this paper
• Population Pharmacokinetic Analysis of Anidulafungin, an Echinocandin Antifungal

  2004cited by this paper
• Low‐dose amphotericin b lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies – a randomized, controlled trial

  2004cited by this paper
• Caspofungin Therapy of Neonates With Invasive Candidiasis

  2004cited by this paper
• Effects of fluid and electrolyte management on amphotericin B-induced nephrotoxicity among extremely low birth weight infants.

  2004cited by this paper
• Pharmacokinetics and Safety of Intravenous Voriconazole in Children after Single- or Multiple-Dose Administration

  2004cited by this paper
• Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients.

  2003influential reference
• In Vivo Pharmacodynamics of a New Triazole, Ravuconazole, in a Murine Candidiasis Model

  2003cited by this paper
• Pharmacokinetics, Safety, and Tolerability of Oral Posaconazole Administered in Single and Multiple Doses in Healthy Adults

  2003cited by this paper

• Review on macrophage polarization during visceral leishmaniasis and impact of glycoprotein

  2026cites this paper
• Circadian considerations in antimicrobials

  2026cites this paper
• Review of Precision Medicine and Diagnosis of Neonatal Illness

  2025cites this paper
• Dosing and safety of amphotericin B deoxycholate in paediatric American cutaneous leishmaniasis in Peru: a case series

  2025cites this paper
• The Potential Use of Peptides in the Fight against Chagas Disease and Leishmaniasis

  2024cites this paper
• Invasive fungal infections in critically ill children: epidemiology, risk factors and antifungal drugs

  2024influential citation
• From Spores to Solutions: A Comprehensive Narrative Review on Mucormycosis

  2024cites this paper
• Perspectives on the Use of Echinocandins in the Neonatal Intensive Care Unit

  2024cites this paper
• Recent Challenges in Diagnosis and Treatment of Invasive Candidiasis in Neonates

  2024cites this paper
• Voriconazole plasma concentrations and dosing in paediatric patients below 24 months of age

  2023cites this paper
• Infections fongiques en pédiatrie

  2023cites this paper
• Updated Perspectives on the Diagnosis and Management of Neonatal Invasive Candidiasis

  2023influential citation
• Infecciones fúngicas en pediatría

  2023cites this paper
• New and emerging options for management of invasive fungal diseases in paediatric patients

  2023cites this paper
• Real-World, Multicenter Case Series of Patients Treated with Isavuconazole for Invasive Fungal Disease in China

  2023cites this paper
• Model-informed precision dosing of antimicrobial drugs in pediatrics: experiences from a pilot scale program

  2023cites this paper
• Isavuconazole Treatment for Invasive Fungal Infections in Pediatric Patients

  2022cites this paper
• Section 4. Colombian consensus on the diagnosis and treatment of chronic, saprophytic and/or allergic syndromes associated with Aspergillus spp. in adult and pediatric patients

  2022cites this paper
• Section 3. Colombian consensus on the diagnosis and treatment of extrapulmonary aspergillosis in adult patients

  2022cites this paper
• Section 1. Colombian consensus on the diagnosis and follow-up of invasive aspergillosis and Aspergillus disease in adult and pediatric patients

  2022cites this paper
• Polyene Antibiotics Physical Chemistry and Their Effect on Lipid Membranes; Impacting Biological Processes and Medical Applications

  2022cites this paper
• Optimisation of fluconazole therapy for the treatment of invasive candidiasis in preterm infants

  2022cites this paper
• Synthesis and Antifungal Activity of N-Benzyl Derivatives of Tetramycin B

  2021cites this paper
• Managing uncertainty in antifungal dosing: antibiograms, therapeutic drug monitoring and drug-drug interactions

  2021cites this paper
• Precision Therapy for Invasive Fungal Diseases

  2021cites this paper
• Advancement in leishmaniasis diagnosis and therapeutics: An update.

  2021cites this paper
• Echinocandins in Pediatric Invasive Candidiasis and the Challenges of Antifungal Use in Children.

  2021cites this paper
• Administration and Dosing of Systemic Antifungal Agents in Pediatric Patients

  2020cites this paper
• Neonatal fluid and electrolytes profile effect on amphotericin B associated nephrotoxicity in neonatal tertiary care unit of Karachi-Pakistan

  2020cites this paper
• Antifungal Penetration and Distribution into Organs and Tissue

  2020cites this paper
• Population Pharmacokinetic Study of Prophylactic Fluconazole in Preterm Infants for Prevention of Invasive Candidiasis

  2019cites this paper
• Antibiotic Considerations for Necrotizing Enterocolitis

  2019cites this paper
• Successful treatment with voriconazole combined with amphotericin B-liposome for fluconazole-resistant pulmonary cryptococcosis after renal transplantation

  2019cites this paper
• Antifungal Drugs for Invasive Candida Infections (ICI) in Neonates: Future Perspectives

  2019cites this paper
• Neonatal Antifungal Consumption Is Dominated by Prophylactic Use; Outcomes From The Pediatric Antifungal Stewardship: Optimizing Antifungal Prescription Study.

  2019cites this paper
• A Case Series and Literature Review of Isavuconazole Use in Pediatric Patients with Hemato-oncologic Diseases and Hematopoietic Stem Cell Transplantation

  2019cites this paper
• Pharmacokinetics and safety of fluconazole and micafungin in neonates with systemic candidiasis: a randomized, open‐label clinical trial

  2018cites this paper
• Optimizing Antibiotic Drug Therapy in Pediatrics: Current State and Future Needs

  2018cites this paper
• Suggestions for Model‐Informed Precision Dosing to Optimize Neonatal Drug Therapy

  2018cites this paper
• Successful treatment of invasive mucormycosis with isavuconazole in pediatric patients

  2018cites this paper
• Comprehensive drug utilization review in neonates: liposomal amphotericin B

  2018cites this paper
• Mucormycosis in Children: Review and Recommendations for Management

  2018cites this paper
• Clinical Relevance of Medicinal Plants and Foods of Vegetal Origin on the Activity of Cytochrome P450

  2018cites this paper
• A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis

  2018cites this paper
• Safety and Efficacy of Micafungin in Extremely Low Birth Weight Infants

  2017cites this paper
• Blood and tissue distribution of posaconazole in a rat model of invasive pulmonary aspergillosis.

  2017cites this paper
• Antifungal Drugs in Newborns and Children.

  2017cites this paper
• Dose optimisation of voriconazole with therapeutic drug monitoring in children: a single-centre experience in China.

  2017cites this paper
• Synthetic Organotellurium Compounds Sensitize Drug-Resistant Candida albicans Clinical Isolates to Fluconazole

  2016cites this paper
• Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections

  2016cites this paper
• [Invasive fungal infections in children: similarities and differences with adults].

  2016cites this paper
• A case of cutaneous Paecilomyces formosus infection in an extremely premature infant.

  2016cites this paper
• Antifungal pharmacodynamics: Latin America's perspective

  2016cites this paper
• New antifungal and antiviral dosing.

  2015cites this paper
• Impact of special patient populations on the pharmacokinetics of echinocandins

  2015cites this paper
• Immunotherapy of Fungal Infections

  2015cites this paper
• Advances in the treatment of invasive neonatal candidiasis

  2015cites this paper
• Clinical pharmacology of antifungal agents to overcome drug resistance in pediatric patients

  2015influential citation
• Assessment of echinocandin regimens by pharmacokinetic/pharmacodynamic analysis against Candida spp. in paediatric patients.

  2015cites this paper
• Clinical Pharmacokinetics of Inhaled Antimicrobials

  2015cites this paper
• Pharmacokinetics and Pharmacodynamics of Antibacterials, Antifungals, and Antivirals Used Most Frequently in Neonates and Infants

  2014cites this paper
• Management of invasive fungal infections in the pediatric intensive care unit

  2014cites this paper
• Pharmacokinetics and Pharmacodynamics of Antibacterials, Antifungals, and Antivirals Used Most Frequently in Neonates and Infants Jessica K. RobertsChris StockmannJonathan E. Constance • Justin StiersMichael G. SpigarelliRobert M. Ward •

  2014cites this paper
• Editorial commentary: Fluconazole therapeutic drug monitoring in children with cancer: not today.

  2014cites this paper